The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
Researchers found that hypoxia was associated with elevated genomic instability in 10 tumor types and saw widespread hypoxia-associated dysregulation of miRNAs.
With a DNA methylation atlas and deconvolution algorithm, researchers are attempting to trace cfDNA back to tissue sources in healthy or ill individuals.
Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.